Samsung finalizes Raypax beta siteKorean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the company’s Raypax PACS product. The clinic will be Samsung’s first U.S. installation of Raypax
Korean PACS firm Samsung has announced that Palo Alto Medical Clinic has agreed to be the beta site for the companys Raypax PACS product. The clinic will be Samsungs first U.S. installation of Raypax since it received 510(k) clearance earlier this year (
PNN
8/99). The system was installed the first week of August, and initially will deal with two modalities, CT and MRI. Samsung, which maintains U.S. operations in San Jose, CA, will work with PAMC to create a version of Raypax that meets the requirements of American radiologists, the company said.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
Could an Emerging PET Tracer be a Game Changer for Detecting Hepatocellular Carcinoma?
June 23rd 2025In addition to over 90 percent sensitivity in detecting hepatocellular carcinoma (HCC), the glypican-3 (GPC3) targeted PET tracer 68Ga-aGPC3-scFv appeared to be advantageous in identifying HCC tumors smaller than one centimeter, according to pilot study findings presented at the SNMMI conference.
SNMMI: What a New Meta-Analysis Reveals About Radiotracers for PET/CT Detection of PCa
June 22nd 2025While (68Ga)Ga-PSMA-11 offers a pooled sensitivity rate of 92 percent for prostate cancer, (18F)-based radiotracers may offer enhanced lesion detection as well as improved imaging flexibility, according to a meta-analysis presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.